Protocols for Lung Cancer
| HIC 0809004248 Scott Gettinger M.D. Sorafenib Long Term Extension Program (STEP) |
| HIC 0708002987 Scott Gettinger M.D. A Phase I/II Trial of Induction Carboplatin/Paclitaxel with Bevacizumab Followed by Concurrent Thoracic Conformal Radiation Therapy with Carboplatin/ Paclitaxel, Bevacizumab and Erlotinib in Stage III A/B Non-small Cell Lung Cancer |
| HIC 0904005074 Scott Gettinger M.D. (ECOG 1505) A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (greater than or equal to 4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC) |
| HIC 0904005075 A Phase 1 Study of IPI-504 and Docetaxel in Patients with Advanced Solid Tumors. |
| HIC 0909005674 Scott Gettinger M.D. A Study of Ridaforolimus (AP23573/MK-8669) in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations |
| HIC 0909005674 Scott Gettinger M.D. A Randomized Discontinuation Phase II Trial of Ridaforolimus (AP23573/MK-8669) in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations |
| HIC 0907005473 Scott Gettinger M.D. A8081007: Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Patients with Advanced Nonsmall Cell Lung Cancer (NSCLC) Harboring a Translocation or |
| HIC 0811004507 Roy Decker M.D., PhD A Dose Escalation Study of Vorinostat in Combination with Palliative Radiotherapy for Patients with Non-Small Cell Lung Cancer |
| HIC 0707002901 Scott Gettinger M.D. Phase I/II Trial of Induction Carboplatin/Paclitaxel with Bevacizumab followed by Concurrent Thoracic Conformal Radiation Therapy with Carboplatin/ Paclitaxel, Bevacizumab and Erlotinib in Stage III A/B Non-small Cell Lung Cancer |
| HIC 0805003786 Scott Gettinger M.D. A Phase 1/2 Study of XL184 with or without Erlotinib in Subjects with Non-Small Cell Lung Cancer |
| HIC 0907005475 Scott Gettinger M.D. A8081005: Phase 2, open-label single arm study of the efficacy and safety of PF-02341066 in patients with advanced non-small cell lung cancer (NSCLC) harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus |
11